VYNE Annual EBIT
-$29.26 M
+$5.04 M+14.69%
31 December 2023
Summary:
As of January 23, 2025, VYNE annual earnings before interest & taxes is -$29.26 million, with the most recent change of +$5.04 million (+14.69%) on December 31, 2023. During the last 3 years, it has risen by +$222.18 million (+88.36%). VYNE annual EBIT is now -534.94% below its all-time high of -$4.61 million, reached on December 31, 2015.VYNE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VYNE Quarterly EBIT
-$13.09 M
-$2.69 M-25.92%
30 September 2024
Summary:
As of January 23, 2025, VYNE quarterly earnings before interest & taxes is -$13.09 million, with the most recent change of -$2.69 million (-25.92%) on September 30, 2024. Over the past year, it has dropped by -$2.69 million (-25.92%). VYNE quarterly EBIT is now -165.81% below its all-time high of -$4.92 million, reached on December 31, 2016.VYNE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VYNE TTM EBIT
-$37.70 M
-$6.86 M-22.23%
30 September 2024
Summary:
As of January 23, 2025, VYNE TTM earnings before interest & taxes is -$37.70 million, with the most recent change of -$6.86 million (-22.23%) on September 30, 2024. Over the past year, it has dropped by -$6.86 million (-22.23%). VYNE TTM EBIT is now -665.46% below its all-time high of -$4.92 million, reached on December 31, 2016.VYNE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VYNE EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.7% | -25.9% | -22.2% |
| 3 y3 years | +88.4% | -64.0% | -9.9% |
| 5 y5 years | +46.4% | -64.0% | -9.9% |
VYNE EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.1% | -122.8% | at low | -28.9% | +3.5% |
| 5 y | 5-year | at high | +88.4% | -122.8% | +92.1% | -28.9% | +85.0% |
| alltime | all time | -534.9% | +88.4% | -165.8% | +92.1% | -665.5% | +85.0% |
VYNE Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$13.09 M(+25.9%) | -$37.70 M(+22.2%) |
| June 2024 | - | -$10.40 M(+40.9%) | -$30.84 M(+0.3%) |
| Mar 2024 | - | -$7.38 M(+8.0%) | -$30.76 M(+5.1%) |
| Dec 2023 | -$29.26 M(-14.7%) | -$6.83 M(+9.6%) | -$29.26 M(-3.8%) |
| Sept 2023 | - | -$6.23 M(-39.6%) | -$30.41 M(-9.2%) |
| June 2023 | - | -$10.32 M(+75.6%) | -$33.51 M(+6.5%) |
| Mar 2023 | - | -$5.88 M(-26.4%) | -$31.48 M(-8.2%) |
| Dec 2022 | -$34.30 M(-12.2%) | -$7.98 M(-14.5%) | -$34.30 M(-2.4%) |
| Sept 2022 | - | -$9.33 M(+12.6%) | -$35.13 M(-4.0%) |
| June 2022 | - | -$8.29 M(-4.6%) | -$36.60 M(-3.5%) |
| Mar 2022 | - | -$8.69 M(-1.5%) | -$37.92 M(-2.9%) |
| Dec 2021 | -$39.05 M(-84.5%) | -$8.82 M(-18.3%) | -$39.05 M(-25.3%) |
| Sept 2021 | - | -$10.80 M(+12.4%) | -$52.25 M(-19.7%) |
| June 2021 | - | -$9.61 M(-2.1%) | -$65.07 M(-70.7%) |
| Mar 2021 | - | -$9.81 M(-55.4%) | -$222.08 M(-11.7%) |
| Dec 2020 | -$251.44 M | -$22.02 M(-6.8%) | -$251.44 M(+0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$23.62 M(-85.8%) | -$251.35 M(+2.5%) |
| June 2020 | - | -$166.63 M(+325.4%) | -$245.15 M(+156.1%) |
| Mar 2020 | - | -$39.17 M(+78.6%) | -$95.74 M(+25.6%) |
| Dec 2019 | -$76.24 M(+39.8%) | -$21.93 M(+25.8%) | -$76.24 M(+4.8%) |
| Sept 2019 | - | -$17.43 M(+1.2%) | -$72.75 M(+5.4%) |
| June 2019 | - | -$17.22 M(-12.5%) | -$69.03 M(+13.2%) |
| Mar 2019 | - | -$19.67 M(+6.7%) | -$60.98 M(+11.8%) |
| Dec 2018 | -$54.53 M(+84.3%) | -$18.44 M(+34.6%) | -$54.53 M(+19.7%) |
| Sept 2018 | - | -$13.70 M(+49.4%) | -$45.57 M(+13.3%) |
| June 2018 | - | -$9.17 M(-30.6%) | -$40.20 M(+7.9%) |
| Mar 2018 | - | -$13.22 M(+39.5%) | -$37.26 M(+25.9%) |
| Dec 2017 | -$29.59 M(+106.5%) | -$9.48 M(+13.7%) | -$29.59 M(+18.2%) |
| Sept 2017 | - | -$8.34 M(+33.9%) | -$25.04 M(+49.9%) |
| June 2017 | - | -$6.22 M(+12.1%) | -$16.70 M(+59.4%) |
| Mar 2017 | - | -$5.55 M(+12.8%) | -$10.48 M(+112.8%) |
| Dec 2016 | -$14.33 M(+211.0%) | -$4.92 M | -$4.92 M |
| Dec 2015 | -$4.61 M | - | - |
FAQ
- What is VYNE Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for VYNE Therapeutics?
- What is VYNE Therapeutics annual EBIT year-on-year change?
- What is VYNE Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly EBIT year-on-year change?
- What is VYNE Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for VYNE Therapeutics?
- What is VYNE Therapeutics TTM EBIT year-on-year change?
What is VYNE Therapeutics annual earnings before interest & taxes?
The current annual EBIT of VYNE is -$29.26 M
What is the all time high annual EBIT for VYNE Therapeutics?
VYNE Therapeutics all-time high annual earnings before interest & taxes is -$4.61 M
What is VYNE Therapeutics annual EBIT year-on-year change?
Over the past year, VYNE annual earnings before interest & taxes has changed by +$5.04 M (+14.69%)
What is VYNE Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of VYNE is -$13.09 M
What is the all time high quarterly EBIT for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly earnings before interest & taxes is -$4.92 M
What is VYNE Therapeutics quarterly EBIT year-on-year change?
Over the past year, VYNE quarterly earnings before interest & taxes has changed by -$2.69 M (-25.92%)
What is VYNE Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of VYNE is -$37.70 M
What is the all time high TTM EBIT for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM earnings before interest & taxes is -$4.92 M
What is VYNE Therapeutics TTM EBIT year-on-year change?
Over the past year, VYNE TTM earnings before interest & taxes has changed by -$6.86 M (-22.23%)